SAREPTA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
SAREPTA THERAPEUTICS, INC. (SRPT) had Debt Securities, Available-for-sale, Amortized Cost of $1.08 billion as of 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-08-07
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.08B.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $963.99M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.25B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-06-30 | $1.08B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $963.99M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.25B 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |